2 Cord blood (CB) mononuclear cells (MNC) are being tested in clinical trials to treat hypoxic-3 ischemic (HI) brain injuries. Although early results are encouraging, mechanisms underlying 4 potential clinical benefits are not well understood. To explore these mechanisms further, we 5 exposed mouse brain organotypic slice cultures to oxygen and glucose deprivation (OGD) and 6 then treated the brain slices with cells from CB or adult peripheral blood (PB). We found that 7 CB-MNCs protect neurons from OGD-induced death and reduced both microglial and astrocyte 8 activation. PB-MNC failed to affect either outcome. The protective activities were largely 9 mediated by factors secreted by CB-MNC, as direct cell-to-cell contact between the injured brain 10 slices and CB cells was not essential. To determine if a specific subpopulation of CB-MNC are 11 responsible for these protective activities, we depleted CB-MNC of various cell types and found 12 that only removal of CB CD14 + monocytes abolished neuroprotection. We also used positively 13 selected subpopulations of CB-MNC and PB-MNC in this assay and demonstrated that purified 14 CB-CD14 + cells, but not CB-PB CD14 + cells, efficiently protected neuronal cells from death and 15 reduced glial activation following OGD. Gene expression microarray analysis demonstrated that 16 compared to PB-CD14 + monocytes, CB-CD14 + monocytes over-expressed several secreted 17 proteins with potential to protect neurons. Differential expression of five candidate effector 18 molecules, chitinase 3-like protein-1, inhibin-A, interleukin-10, matrix metalloproteinase-9 and 19 thrombospondin-1, were confirmed by western blotting, and immunofluorescence. These 20 findings suggest that CD14 + monocytes are a critical cell-type when treating HI with CB-MNC. 21 4 1
1 microglial cells in each max projection image using Fiji (ImageJ). Each image was thresholded 2 by eye to convert each 32-bit grayscale image to a compatible 8-bit image with an inverted LUT.
3 The freehand selection tool was utilized to appropriately select the desired microglial cell and 4 clear the outside. The straight-line tool was used to define the largest Sholl radius, beginning in 5 the center of the cell and arbitrarily extending outward. Sholl analysis was performed under the 6 'most informative' normalized profile, which auto-determines whether to use a semi-log or log-7 log method of analysis [26] . Area was used as the normalizer in each profile. Parameters were set 8 with a beginning radius of 5 microns, an ending radius of 49 microns, and a step size of 2 9 microns. The enclosing radius cutoff was set at 1 intersection. Data presented in the associated 10 figure (Fig 2) was deduced at by averaging the number of intersections per step size per group.
11
12 Isolation of human umbilical cord and adult peripheral blood mononuclear cells 13 Freshly collected human umbilical cord blood was provided by the Carolinas Cord Blood Bank 14 at Duke, an FDA licensed public cord blood bank that accepts donations of cord blood collected 15 after birth from the placentas of healthy term newborns after written informed consent from the 16 baby's mother. Also with maternal informed consent, cord blood units not qualifying for banking 17 for transplantation were designated for research and made available for this study. Peripheral 18 blood (PB) was obtained via venipuncture from healthy adult volunteer donors. Procurement of 19 human samples were obtained using protocols approved by the Duke University Institutional 20 Review Board. Mononuclear cells were isolated from CB and PB by density centrifugation using 21 standard Ficoll-Hypaque technique (GE Healthcare) then treated with 0.15M NH 4 Cl to lyse 22 residual erythrocytes and washed in phosphate-buffered saline (PBS).
Immunomagnetic cell isolation of various sub-populations of CB and PB experiments
2 Specific sub-populations were isolated or removed from CB-MNC or PB-MNC by 3 immunomagnetic sorting using EasySep cell kits for human CD34 + , CD3 + , CD14 + and CD19 + 4 cells (Stemcell Technologies, Vancouver, Canada, Catalog #18096, #18051, #18058 and #18054 5 respectively) following the manufacturer's directions. Flow-through fractions from positive 6 selection columns were re-run through the columns to increase the purity of targeted populations. 7 A sample of each cell preparation was analyzed by flow cytometry to determine cellular 8 composition [27] . Immuno-magnetically selected specific sub-population of cells with ≥80% 9 purity was used for any experiment. More highly purified populations were obtained by cell 10 sorting as described below for gene expression analysis.
11
12 RNA isolation and microarray analysis 13 RNA isolation and microarray analysis were carried out exactly as described previously using 14 54,675 probe set Affymetrix GeneChip Human Transcriptome Array 2.0 microarrays and Partek 15 Genomics Suite 6.6 (Partek Inc., St. Louis, MO) software for analysis [27] . S1 Table outlines 1 Western blotting 2 Western blotting was carried out as previously described [27] using antibodies described in S1
3 Table. 4 5 Statistical analysis:
6 Data analysis was performed by calculating the mean of the values for each individual 7 group ± standard error of mean and shown, graphically. Statistical analyses were carried out with 8 GraphPad Prism software. All comparisons were performed by one-way analysis of variance 9 (ANOVA) followed by post-hoc analysis with Bonferroni correction. Mean differences were 10 considered significant if p<0.05 was computed. 
CB-MNC protect organotypic brain slice culture cells from OGD induced damage
3 Mouse brain organotypic slice cultures were exposed to OGD for 1-hour and returned to the 4 normoxic condition with media containing glucose for the cell treatment. A schematic diagram 5 of the organotypic brain slice culture system is shown in S1A Fig. The extent of damage in the 6 brain slice culture was evaluated by cellular PI uptake after the ischemic insult and following cell 7 treatment. We found a significant number of cells in mouse brain slice cultures became 8 permeable to PI during the three days following OGD shock Fig 1A. Addition of 25,000 CB-9 MNC to the surface of each OGD-shocked brain slice reduced the number of PI-stained dead To determine if paracrine factors released from CB-MNC contribute to their neuroprotective 21 effects on OGD-shocked brain slices, we added CB-MNC to the medium below the membrane 22 instead of directly onto the OGD-shocked slices. This prevented direct contact between CB-23 MNC and brain cells, but permitted agents secreted by CB-MNC to access to the cells in the 1 brain slices through the 0.4µm pores. To compensate for possible dilution of protective factors 2 by the large volume the culture medium, we added 1.25x10 5 cells below the membrane. Adding 3 CB-MNC below the membrane reduced brain cell death ( Fig 1C) . Thus, neuroprotection by CB-4 MNC after OGD is mediated at least in part through secreted factors.
5 To identify what cell-types within CB-MNC mediated neuroprotection following OGD, we 6 tested the ability of CB-MNC depleted of specific cell populations as well as isolating specific 7 populations of cell from CB-MNC in our above organotypic cell death assay.
8 Immunomagnetically enriched CD14 + monocytes from CB were sufficient to protect slices from 9 OGD, and CB-MNC depleted of CD14 + monocytes were no longer able to confer protection ( Fig   10 1 D) . Depleting other populations, e.g CD3 + T-lymphocyte or CD19 + B-lymphocytes or CD34 + 11 hematopoietic progenitor cells from CB-MNCs did not block protection.
13 CB CD14 + monocytes protect neurons and reduce glial activation
14 CB-CD14 + monocytes preserved neurons and dampened microglial and astrocytic activation 15 following OGD. Cell death following OGD was mirrored by a large decrease in the NeuN-16 positive neuronal nuclei (Fig 2A and Fig 2B) . Astrocytes in the cultures that were treated with 17 OGD became hypertrophic and extended multiple processes taking on a characteristic activated 18 morphology ( Fig 2C) [28, 29] . Astrocytes were less activated in CB-CD14 + treated slices than 19 CD14-depleted CB-MNC or untreated OGD slices ( Fig 2C) . It is well established that microglial 20 change morphology from a highly ramified resting state to a reactive/amoeboid state upon 21 ischemic insult [30] . To visualize the microglial morphological change much easily we initiated 22 the organotypic brain slice cultures using CX3CR1-GFP + /-mice P2 pups. Sholl analysis of these 1 morphological changes reflecting microglial activation showed that CB-monocytes prevented 2 microglial proliferation and activation in slices exposed to OGD (Fig 2D-Fig 2F) .
4 PB-MNC or purified PB-CD14 + cells failed to protect from OGD induced tissue damage
5 Since PB-MNC are plentiful in patients with unresolved HI induced injuries we hypothesized 6 that PB-MNCs would not protect against OGD insult. Unlike CB-MNCs, PB-MNCs, CD14 + 7 depleted PB-MNC, or isolated CD14 + -PB monocytes were unable to prevent cell death ( Fig 3A) 8 or loss of neurons ( Fig 3B) , following OGD insult. 9 The differences in activity between CB-MNC and PB-MNC provided an approach to begin to 10 explore the mechanisms by which CB-MNC protect brain cells from hypoxic injury. We 11 reasoned that transcripts for mechanistically important factors would be over-expressed in CB-12 MNC relative to PB-MNC. To identify these transcripts, we compared whole transcriptome 13 microarrays analysis of CB-and PB-MNC. As described in the Supporting Information section, 14 in all, we analyzed seven adult PB donors and seven CB donors in two separate experiments 15 (714 and 1213) and found that CB and PB-CD14 + monocytes have unique mRNA expression 16 profiles. A heat map presentation of the data analysis of experiment experiments 1213 ( Fig 4A) , 17 for example, shows that CB and PB-CD14 + monocytes differentially expressed 1553 transcripts.
18 Of these, 474 probes detected transcripts expressed only in PB-CD14 + monocytes, and another 19 204 probes detected transcript only expressed in CB-CD14 + monocytes. CB and PB-CD14 + 20 monocytes fall into discrete populations defined by these differentially expressed transcripts.
21 Since CB monocytes protect at least in part through secreted factors, we determined which 22 differentially expressed genes (identified in both experimental analyses) encoded secreted 23 proteins or proteins that directly synthesized secreted products. Seven candidates emerged from 2 and PB CD14 + monocytes ( Fig 4C) . CB monocytes expressed more CHI3L1, INHBA, IL10, 3 MMP9, and TSP1 than PB-CD14 + monocytes. Cystathionine (CTH) and VEGFA were strongly, 4 but not differentially, expressed by both CB-and PB-MNC (data not shown). We also used 5 immunocytochemistry to determine how CHI3L1, MMP9 and TSP1 proteins were expressed 6 within CB and PB-CD14 + monocyte populations. S2 Fig shows that CHI3L1 and TSP1 were 7 more strongly expressed in CB than PB-CD14 + monocytes and that these two proteins were 8 present in virtually all CD14 + monocytes. CB monocytes also expressed more MMP9 than PB 9 monocytes, but in this case, expression was confined to a subpopulation of CD14 + monocytes 10 that was less common in PB monocyte populations. 2 We demonstrated that CB-MNC, specifically the CB-CD14 + cells, protect neurons from death 3 after OGD insult. Depleting CD14 + cells, but not other cell types, abrogated the neuroprotective 4 effects of CB-MNC. Purified CD34 + cells also have neuroprotective activity, but given that 5 depleting CD34 + cells did not alter neuroprotection and that CD14 + cells are 10-50-fold more 6 abundant in CB MNC than CD34 + cells, we attribute the neuroprotective activity of CB-MNC in 7 our assay system to CD14 + cells. Neuroprotection was mediated primarily by soluble factors 8 produced by CD14 + monocytes. This corroborates previous studies demonstrating that 9 infiltrating monocytes sequestered in the brain meninges modulate brain inflammation and 10 promote repair following HI injuries [31, 32] . CB CD14 + monocytes used as a therapeutic agent 11 may have similar effects whether administered alone as a selected subpopulation or as a 12 component present in the total CB-MNC.
13 Unlike CB monocytes, PB monocytes had little or no impact on glial activation or cell death in 14 the OGD assay. We identified differentially expressed genes enriched in CB monocytes 15 compared to PB monocytes. Based on our transwell experiments and other published data [10,
16 14] demonstrating that CB-MNC mediated repair of brain tissue through paracrine factors, we 17 focused on finding secretory molecules over expressed in CB monocytes. Proteins encoded by 18 five (CHI3L1, TSP1, MMP9, IL10, and INHBA) 21 including repair in the brain. TSP1, CHI3l1 and MMP9 showed the largest difference in protein 22 expression, and CB monocytes have more of these three proteins in cytoplasmic granules, 23 presumably secretory granules, than PB monocytes. Thus, CHI3l1, TSP1, and MMP9 may be 1 particularly important in paracrine mechanisms by which CB monocytes reduce glial activation 2 and protect brain neurons from OGD. Furthermore, correlating the biological and clinical 3 activities with expression of these markers may provide a path to a biologically based potency 4 assay for CB products in brain repair indications.
5 Though our work suggests that secretory proteins CHI3l1, TSP1, and MMP9 from monocytes 6 might contribute to neuroprotection, other important protective gene products are probably 7 induced by CB monocytes in or near HI-shocked brain tissue. The OGD-shocked brain slice 8 model should be useful in identifying these gene products and elucidating more precisely how 9 CB monocytes intervene in the pathogenic process.
10 Finally, most preclinical studies and clinical trials involving the use of CB-MNC as therapeutics 11 for HI brain injuries have involved intravenous delivery of cell product. The OGD model in 12 which cells are added directly to brain slices, or in a small amount of medium directly below the 13 slices, may not reflect the dosing or pharmacokinetics associated with intravenous 14 administration. We found a dose dependency over a ten-fold range of CB monocyte 15 concentration in the OGD model even though cells were directly applied to slices. In 16 hematopoietic stem cell transplant patients receiving intravenously injected CB-MNC grafts, 17 most CB cells are removed in the lungs and other organs during first pass circulation. Animal 18 studies have shown that some unidentified CB cells are present near brain lesions for short 19 periods of time following intravenous treatment of acute stroke [50] or neonatal HIE with CB-20 MNC [51] but the function of these cells is unclear. Some evidence suggests that CB-MNC 21 respond to chemokines by migrating to ischemic brain regions [52] [53] [54] . Womble et al. found that 22 the beneficial activity of intravenously injected CB-MNC in a rat stroke model resided in the 23 CD14 + monocyte population. How many CB-MNC or monocytes that reach the brain following 1 intravenous injection in patients with HI-induced brain injury is unknown. Indeed, some animal 2 studies have suggested that intravenously injected CB-MNC products [55] do not need to reach 3 the brain in order to promote repair of stroke or other HI brain injury. Instead, cell products 4 reaching the lungs or spleen may induce endogenous cells to produce soluble factors or activated 5 cells that go to the brain and mediate repair [56] [57] [58] . Future studies investigating the 6 biodistribution of CB monocytes will determine the most effective route and dose for 7 administration.
8 In summary, monocytes in CB, but not PB, protect brain neurons from death and reduce glial 9 activation following HI insult in an in vitro OGD model. Soluble factors released from CB 10 monocytes contribute to this protection. We have identified secreted proteins enriched in CB 11 CD14 + monocytes compared to PB monocytes that may play a role in neuroprotection and repair.
12 This work enables future detailed study of the mechanism of neuroprotection and development 13 of mechanism-based release assays for CB products, and formulation of new strategies for using 14 CB monocytes as therapeutic agents in treatment of HI-induced brain injuries. 
